Literature DB >> 19464559

Vaccination with vif-deleted feline immunodeficiency virus provirus, GM-CSF, and TNF-alpha plasmids preserves global CD4 T lymphocyte function after challenge with FIV.

Saipiroon Maksaereekul1, Robert A Dubie, Xiaoying Shen, Hung Kieu, Gregg A Dean, Ellen E Sparger.   

Abstract

Feline immunodeficiency virus (FIV) DNA vaccine approaches that included a vif-deleted FIV provirus (FIV-pPPRDeltavif) and feline cytokine expression plasmids were tested for immunogenicity and efficacy by immunization of specific pathogen free cats. Vaccine protocols included FIV-pPPRDeltavif plasmid alone; a combination of FIV-pPPRDeltavif DNA and feline granulocyte macrophage-colony stimulating factor (GM-CSF) and tumor necrosis factor (TNF)-alpha expression plasmids; or a combination of FIV-pPPRDeltavif and feline interleukin (IL)-15 plasmids. Cats immunized with FIV-pPPRDeltavif, GM-CSF and TNF-alpha plasmids demonstrated an increased frequency of FIV-specific T cell proliferation responses compared to other vaccine groups. Immunization with FIV-pPPRDeltavif and IL-15 plasmids was distinguished from other vaccine protocols by the induction of antiviral antibodies. Suppression of virus loads was not observed for any of the FIV-pPPRDeltavif DNA vaccine protocols after challenge with the FIV-PPR isolate. However, prior immunization with FIV-pPPRDeltavif, GM-CSF, and TNF-alpha plasmids resulted in preservation of CD4 T cell functions, including mitogen-induced cytokine expression and antigen-specific proliferation upon infection with FIV. These findings justify further examination of cytokine combinations as adjuvants for lentiviral DNA vaccines.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19464559      PMCID: PMC2802579          DOI: 10.1016/j.vaccine.2009.03.081

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  70 in total

Review 1.  Cytokine, chemokine, and costimulatory molecule modulation to enhance efficacy of HIV vaccines.

Authors:  Jeffrey D Ahlers; Igor M Belyakov; Jay A Berzofsky
Journal:  Curr Mol Med       Date:  2003-05       Impact factor: 2.222

2.  AIDS vaccination studies with an ex vivo feline immunodeficiency virus model: analysis of the accessory ORF-A protein and DNA as protective immunogens.

Authors:  Mauro Pistello; Francesca Bonci; J Norman Flynn; Paola Mazzetti; Patrizia Isola; Elisa Zabogli; Valentina Camerini; Donatella Matteucci; Giulia Freer; Paolo Pelosi; Mauro Bendinelli
Journal:  J Virol       Date:  2006-09       Impact factor: 5.103

3.  Studies on GM-CSF DNA as an adjuvant for neutralizing Ab elicited by a DNA/MVA immunodeficiency virus vaccine.

Authors:  Harriet L Robinson; David C Montefiori; Francois Villinger; James E Robinson; Sunita Sharma; Linda S Wyatt; Patricia L Earl; Harold M McClure; Bernard Moss; Rama Rao Amara
Journal:  Virology       Date:  2006-06-05       Impact factor: 3.616

Review 4.  Homeostasis of memory T cells.

Authors:  Charles D Surh; Onur Boyman; Jared F Purton; Jonathan Sprent
Journal:  Immunol Rev       Date:  2006-06       Impact factor: 12.988

5.  Normalized CD8+ but not CD4+ lymphocyte IL-2 expression is associated with early treatment with highly active antiretroviral therapy.

Authors:  Toks Akerele; Grazyna Galatowicz; Catey Bunce; Virginia Calder; William A Lynn; Susan Lightman
Journal:  Clin Immunol       Date:  2006-09-20       Impact factor: 3.969

6.  Global dysfunction of CD4 T-lymphocyte cytokine expression in simian-human immunodeficiency virus/SIV-infected monkeys is prevented by vaccination.

Authors:  Paul F McKay; Dan H Barouch; Jörn E Schmitz; Ronald S Veazey; Darci A Gorgone; Michelle A Lifton; Kenneth C Williams; Norman L Letvin
Journal:  J Virol       Date:  2003-04       Impact factor: 5.103

Review 7.  Lessons from the cat: development of vaccines against lentiviruses.

Authors:  Stephen P Dunham
Journal:  Vet Immunol Immunopathol       Date:  2006-05-05       Impact factor: 2.046

Review 8.  The biology of interleukin-2 and interleukin-15: implications for cancer therapy and vaccine design.

Authors:  Thomas A Waldmann
Journal:  Nat Rev Immunol       Date:  2006-08       Impact factor: 53.106

9.  Feline immunodeficiency virus ORF-Ais required for virus particle formation and virus infectivity.

Authors:  Malou C Gemeniano; Earl T Sawai; Christian M Leutenegger; Ellen E Sparger
Journal:  J Virol       Date:  2003-08       Impact factor: 5.103

10.  Lack of toxicity and persistence in the mouse associated with administration of candidate DNA- and modified vaccinia virus Ankara (MVA)-based HIV vaccines for Kenya.

Authors:  T Hanke; A J McMichael; Rachel V Samuel; L A J Powell; L McLoughlin; S J Crome; A Edlin
Journal:  Vaccine       Date:  2002-11-22       Impact factor: 3.641

View more
  3 in total

1.  Env-expressing autologous T lymphocytes induce neutralizing antibody and afford marked protection against feline immunodeficiency virus.

Authors:  Mauro Pistello; Francesca Bonci; Elisa Zabogli; Francesca Conti; Giulia Freer; Fabrizio Maggi; Mario Stevenson; Mauro Bendinelli
Journal:  J Virol       Date:  2010-02-03       Impact factor: 5.103

2.  Enhancement of DNA Vaccine-induced Immune Responses by Influenza Virus NP Gene.

Authors:  So Young Choi; You Suk Suh; Jae Ho Cho; Hyun Tak Jin; Jun Chang; Young Chul Sung
Journal:  Immune Netw       Date:  2009-10-30       Impact factor: 6.303

3.  Replacement of feline foamy virus bet by feline immunodeficiency virus vif yields replicative virus with novel vaccine candidate potential.

Authors:  Carmen Ledesma-Feliciano; Sarah Hagen; Ryan Troyer; Xin Zheng; Esther Musselman; Dragana Slavkovic Lukic; Ann-Mareen Franke; Daniel Maeda; Jörg Zielonka; Carsten Münk; Guochao Wei; Sue VandeWoude; Martin Löchelt
Journal:  Retrovirology       Date:  2018-05-16       Impact factor: 4.602

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.